Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2007.15.2546 on April 21 2008

Journal of Clinical Oncology, Vol 26, No 16 (June 1), 2008: pp. 2761-2766
© 2008 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by San-Miguel, J.
Right arrow Articles by Anderson, K. C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by San-Miguel, J.
Right arrow Articles by Anderson, K. C.

REVIEW ARTICLE

Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents

Jesús San-Miguel, Jean-Luc Harousseau, Douglas Joshua, Kenneth C. Anderson

From the Servicio de Hematología, Hospital Universitario de Salamanca (Centro de Investigación del Cáncer–Instituto de Biología Molecular del Centro del Cáncer, Universidad de Salamanca-Consejo Superior de Investigaciones Científicas) Salamanca, Spain; University Hospital Nantes, Nantes, France; Institute of Hematology, Royal Prince Alfred Hospital, Sidney, Australia; and the Dana-Farber Cancer Institute, Boston, MA

Corresponding author: Jesús San-Miguel, MD, PhD, Servicio de Hematología, Hospital Universitario de Salamanca, Paseo de San Vicente, 58, 37007 Salamanca, Spain; e-mail: sanmigiz{at}usal.es

Progress in the understanding of multiple myeloma (MM) cell biology has led to the identification of new relevant prognostic factors and subsequently different risk groups. This concept, together with the recent discovery of new drugs with novel mechanisms of action, will probably lead to individualized treatment according to the different patients’ characteristics. In this review, we focus on current available agents already approved for MM, and discuss individualized treatment approaches for both transplantation candidates (subdivided into standard and high-risk patients) and elderly patients. Future progress in MM will be based on using science to inform the design of the optimal combined treatments, and high throughput assays that can assess the ability of combination therapies to induce death of MM cells, both alone and in the bone marrow microenvironment.

published online ahead of print at www.jco.org on April 21, 2008.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.




This article has been cited by other articles:


Home page
NEJMHome page
B. G.M. Durie
Treatment of Myeloma -- Are We Making Progress?
N. Engl. J. Med., August 28, 2008; 359(9): 964 - 966.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online